Today: 29 April 2026
TTWO stock climbs after Wedbush calls Take-Two a ‘Best Idea’ ahead of earnings
2 February 2026
1 min read

TTWO stock climbs after Wedbush calls Take-Two a ‘Best Idea’ ahead of earnings

New York, Feb 2, 2026, 2:05 PM EST — Regular session

  • Take-Two shares were up about 2% in afternoon trading, rebounding after last week’s sharp swings.
  • Wedbush Securities put the videogame publisher on its “Best Ideas” list and kept a $300 price target.
  • Investors are positioning for Take-Two’s fiscal third-quarter results due after Tuesday’s close.

Take-Two Interactive Software shares rose 1.9% to $224.56 in afternoon trading on Monday after Wedbush added the videogame publisher to its “Best Ideas” list. The stock traded between $221.28 and $229.00, with about 2.5 million shares changing hands. Proactiveinvestors NA

The move comes a day before Take-Two reports fiscal third-quarter results after the market close on Tuesday and hosts a conference call at 4:30 p.m. Eastern. The company publishes games through Rockstar Games, 2K and Zynga, and its shares trade on Nasdaq under the TTWO ticker.

What matters now is the tone on outlook. Investors want to hear whether management’s pipeline assumptions have changed and whether the company offers any fresh color around Grand Theft Auto VI, which has become a focal point for expectations.

AI anxiety has added a new wrinkle to the trade. “From a purely game creation perspective, we don’t see AAA studios losing their value proposition,” said Alicia Reese — using shorthand for big-budget blockbuster games — as investors debate whether Google’s Project Genie changes the long-term economics of game development. Bloomberg.com

The early-February tape has been jumpy, and the videogame names have moved with it. Wedbush’s note flagged “Generative Gaming” worries that have weighed on stocks such as Roblox and Unity Software, while arguing Project Genie is “a tool, not a competitor,” for premium content.

Broader markets were also firmer, with Wall Street’s main indexes higher on a rebound in heavyweight tech shares and strength in memory-related stocks. “We’re seeing some stabilization in markets,” said Art Hogan of B. Riley Wealth, as traders shifted attention to a busy earnings week. Reuters

For Take-Two, the read-through will come down to a few lines in the outlook and how management frames the release slate. Traders tend to watch “net bookings” — a metric the company uses to capture sales activity, including timing effects tied to digital purchases — alongside commentary on engagement and spending inside existing franchises.

There is risk on both sides. A strong print may not be enough if guidance is cautious, and any hint of another slip in big-title timing can hit a stock that is priced for execution.

The flip side is simple: if management sticks to its messaging and offers clean enough numbers, Monday’s bid can hold. If not, it won’t take much to turn this back into a sell-the-news move.

Next up is Tuesday’s results after the close, followed by the 4:30 p.m. ET call — the first real chance in week

s for investors to press management on the outlook, and the first catalyst the stock has in hand this week.

Stock Market Today

  • Mesoblast Shares Falter Amid Growing Uncertainty Over Growth Prospects
    April 28, 2026, 10:58 PM EDT. Mesoblast (ASX:MSB) shares closed at A$2.15, down 6.5% over the past week despite a 0.5% gain in the last day. The biopharma firm shows mixed signals: positive 1- and 3-year shareholder returns contrast with weaker short-term performance. Analysts highlight Mesoblast as 43.9% undervalued with a fair value target of A$3.83, driven by heart failure drug rexlemestrocel L, pending potential U.S. accelerated FDA approval. However, risks loom from slow Ryoncil sales and trial delays. Valuation models conflict; discounted cash flow suggests undervaluation at A$3.05, but a high price-to-sales ratio of 30.5x versus industry norms raises questions if the market overpays for growth or if assumptions are overstretched. Investors remain cautious amid uncertain future earnings and regulatory hurdles.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Cisco stock pops to a fresh 52-week high — here’s what Wall Street is watching next
Previous Story

Cisco stock pops to a fresh 52-week high — here’s what Wall Street is watching next

Nebius (NBIS) stock rebounds after a wild session as Feb. 12 results loom
Next Story

Nebius (NBIS) stock rebounds after a wild session as Feb. 12 results loom

Go toTop